Lenvima (lenvatinib mesylate) was approved and launched for differentiated thyroid cancer in the US, the EU and Japan last year, and earned 1.3bn yen (around $12m) in the first quarter of 2016.

The cost of Lenvima can vary based on several factors, including your insurance coverage. Coupons and drug savings programs can also lower the price you’ll pay for Lenvima. As with all ...

Lenvima is taking on Bayer's Nexavar in liver cancer in Japan – a drug that has been on the market for around a decade. According to Hendler the uptake in Japan has been remarkable, and more ...

For patients with unresectable, non-metastatic hepatocellular carcinoma, Lenvima plus Keytruda in combination with TACE improved outcomes. Among patients with unresectable, non-metastatic ...

Patients took two pills of Lenvimab and an IV infusion of ... for answers after his death “This regimen of KEYTRUDA and Lenvima is really one of our most powerful treatment regimens.